Skip to main content
Erschienen in: Indian Journal of Gastroenterology 3/2015

01.05.2015 | Original Article

Acute-on-chronic liver failure: A prospective study to determine the clinical profile, outcome, and factors predicting mortality

verfasst von: Deepak Amarapurkar, Mrudul V Dharod, Madhuri Chandnani, Rajiv Baijal, Praveen Kumar, Mayank Jain, Nikhil Patel, Praful Kamani, Sanjeev Issar, Nimish Shah, Sandeep Kulkarni, Sonali Gautam, Apurva Shah, Soham Doshi

Erschienen in: Indian Journal of Gastroenterology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute-on-chronic liver failure (ACLF), defined differently by different associations, lacks consensus on clinical profile, precipitating events and factors predicting mortality. This prospective multicentric study was conducted to determine the relevance of European Association for Study of Liver (EASL) and Asia Pacific Association for Study of Liver (APASL) definitions and to determine prognostic factors predicting the survival.

Methods

Consecutive patients over a 3-month period with any form of acute deterioration were evaluated for presence of ACLF, as defined by APASL or EASL-Chronic Liver Failure (CLIF) criteria. Those enrolled underwent complete evaluation for identifying the acute insults, underlying chronic etiologies, presence of organ failures, and short-term survival.

Results

Sixty-two patients (median age 53 years, 51 males) who presented with either raised bilirubin (n = 52), international normalized ratio (INR) >1.5 (n = 46), new onset ascites (n = 53), or hepatic encephalopathy (n = 39) were included in study. Forty-four patients (36 males, 25 alcoholics) satisfied APASL definition of ACLF, with a mortality rate of 43.1 %. Hepatic encephalopathy (p-value 0.022) was significantly associated with mortality. By CLIF-Sequential Organ Failure Assessment (SOFA) score criteria for organ failure, 50 patients (80.6 %) had at least 1 organ failure whereas 15 had ≥3 organ failures (mortality rate >75 %). Twenty-nine patients classified as ACLF (1, 2, or 3) as per EASL-CLIF criteria. Bacterial infection, >1 precipitating event, additional organ failure, total leukocyte count, INR, and serum creatinine were significantly higher in patients with ACLF across all grades. Mortality rates were 6.6 and >60 % in patients with ACLF only by APASL criteria vs. by both criteria, respectively.

Conclusions

ACLF, as defined by APASL in terms of liver failure, identified some patients with better survival rates as compared to EASL-CLIF definition which identifies presence of additional organ failures and high mortality.
Literatur
1.
Zurück zum Zitat Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002;20:252–61.PubMedCrossRef Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002;20:252–61.PubMedCrossRef
2.
Zurück zum Zitat Jalan R, Stadlbauer V, Sen S, et al. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care. 2012;16:R227.PubMedCentralPubMedCrossRef Jalan R, Stadlbauer V, Sen S, et al. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care. 2012;16:R227.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269–82.PubMedCentralPubMedCrossRef Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269–82.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Moreau R, Gines P, Jalan R, et al. Diagnosis, prevalence, and prognosis of acute-on-chronic liver failure (ACLF): results of the EASL-chronic liver failure (CLIF) consortium canonic study. J Hepatol. 2012;56:S552–3. Moreau R, Gines P, Jalan R, et al. Diagnosis, prevalence, and prognosis of acute-on-chronic liver failure (ACLF): results of the EASL-chronic liver failure (CLIF) consortium canonic study. J Hepatol. 2012;56:S552–3.
5.
Zurück zum Zitat Garg H, Kumar A, Garg V, et al. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis. 2012;44:166–71.PubMedCrossRef Garg H, Kumar A, Garg V, et al. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis. 2012;44:166–71.PubMedCrossRef
6.
Zurück zum Zitat Krishna YR, Saraswat VA, Das K, et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 2009;29:392–8.CrossRef Krishna YR, Saraswat VA, Das K, et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 2009;29:392–8.CrossRef
7.
Zurück zum Zitat Zheng MH, Shi KQ, Fan YC, et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol. 2011;9:351–6.PubMedCrossRef Zheng MH, Shi KQ, Fan YC, et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol. 2011;9:351–6.PubMedCrossRef
8.
Zurück zum Zitat Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–10. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–10.
9.
Zurück zum Zitat Rastogi A, Kumar A, Sakhuja P, et al. Liver histology as predictor of outcome in patients with acute-onchronic liver failure (ACLF). Virchows Arch. 2011;459:121–7.PubMedCrossRef Rastogi A, Kumar A, Sakhuja P, et al. Liver histology as predictor of outcome in patients with acute-onchronic liver failure (ACLF). Virchows Arch. 2011;459:121–7.PubMedCrossRef
10.
Zurück zum Zitat Huang K, Hu JH, Wang HF, et al. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol. 2011;17:3448–52.PubMedCentralPubMedCrossRef Huang K, Hu JH, Wang HF, et al. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol. 2011;17:3448–52.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Zhihui X, Xiaoqiang R, Yan L, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol. 2011;46:391–400.CrossRef Zhihui X, Xiaoqiang R, Yan L, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol. 2011;46:391–400.CrossRef
12.
Zurück zum Zitat Acharya SK, Sharma PK, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol. 2007;46:387–94.CrossRef Acharya SK, Sharma PK, Singh R, et al. Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol. 2007;46:387–94.CrossRef
13.
Zurück zum Zitat Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol. 2008;23:883–7.PubMedCrossRef Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol. 2008;23:883–7.PubMedCrossRef
14.
Zurück zum Zitat Radha Krishna Y, Saraswat VA, Das K, et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 2009;29:392–8.PubMedCrossRef Radha Krishna Y, Saraswat VA, Das K, et al. Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis. Liver Int. 2009;29:392–8.PubMedCrossRef
15.
Zurück zum Zitat Duseja A, Chawla YK, Dhiman RK, et al. Non-hepatic insults are common acute precipitants in patients with acute-on-chronic liver failure (ACLF). Dig Dis Sci. 2010;55:3188–92.PubMedCrossRef Duseja A, Chawla YK, Dhiman RK, et al. Non-hepatic insults are common acute precipitants in patients with acute-on-chronic liver failure (ACLF). Dig Dis Sci. 2010;55:3188–92.PubMedCrossRef
16.
Zurück zum Zitat Malik R, Mookerjee RP, Jalan R. Infection and inflammation in liver failure: two sides of the same coin. J Hepatol. 2009;51:426–9.PubMedCrossRef Malik R, Mookerjee RP, Jalan R. Infection and inflammation in liver failure: two sides of the same coin. J Hepatol. 2009;51:426–9.PubMedCrossRef
17.
Zurück zum Zitat Xia Q, Dai X, Zhang Y, et al. A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients. PLoS One. 2013;8:e64379.PubMedCentralPubMedCrossRef Xia Q, Dai X, Zhang Y, et al. A modified MELD model for Chinese pre-ACLF and ACLF patients and it reveals poor prognosis in pre-ACLF patients. PLoS One. 2013;8:e64379.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004;10:1099–106.PubMedCrossRef Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004;10:1099–106.PubMedCrossRef
20.
Zurück zum Zitat Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 2004;10:1109–19.PubMedCrossRef Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 2004;10:1109–19.PubMedCrossRef
Metadaten
Titel
Acute-on-chronic liver failure: A prospective study to determine the clinical profile, outcome, and factors predicting mortality
verfasst von
Deepak Amarapurkar
Mrudul V Dharod
Madhuri Chandnani
Rajiv Baijal
Praveen Kumar
Mayank Jain
Nikhil Patel
Praful Kamani
Sanjeev Issar
Nimish Shah
Sandeep Kulkarni
Sonali Gautam
Apurva Shah
Soham Doshi
Publikationsdatum
01.05.2015
Verlag
Springer India
Erschienen in
Indian Journal of Gastroenterology / Ausgabe 3/2015
Print ISSN: 0254-8860
Elektronische ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-015-0574-3

Weitere Artikel der Ausgabe 3/2015

Indian Journal of Gastroenterology 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.